Velacast is indicated for the treatment of adult patients with chronic hepatitis C virus of genotypes 1, 2, 3, 4, 5 or 6
Manufacturer: Natco (India)
Packing: 28 tablets
Velakast belongs to the category of licensed generics. This is a copy of an American antivirus tool developed by Gilead Sciences, Inc. Velakast became the Indian analogue of the medicine from Natco Pharma, a feature of which was the combination of two strong active ingredients at once – sofosbuvir and velpatasvir, which is 10% more effective than taking the first component with ledipasvir or daclatasvir.
Sofosbuvir (sofosbuvir) and Velpatasvir (velpatasvir)
Each Velakast tablet contains:
- Sofosbuvir – 400 mg
- Velpatasvir –100 mg
Along with the main active substances in Velakast are additional ingredients:
- fine crystalline cellulose;
- croscarmellose sodium;
- iron oxide (III);
- magnesium stearate;
- polyvinyl alcohol;
- titanium dioxide.
Each jar contains 28 tablets and is closed by a lid with protection against children.
The slightly oblong and oval Velakast pills have a film coating that facilitates oral administration. Packaging from Natco Pharma has a corporate identity: a combination of white and green shades, company symbols, indication of active ingredients and manufacturer.
For maximum tightness, the can has a tight lid and a protective layer of foil, which reduces the likelihood of water ingress and limits the access of children. The cardboard packaging contains instructions for taking the medicine.
Store the drug at a temperature below 30 ° Celsius in a dry and dark place with protection from children.
Indications for use
Velacast is indicated for the treatment of adult patients with chronic hepatitis C virus of genotypes 1, 2, 3, 4, 5 or 6:
without cirrhosis or with compensated cirrhosis,
with decompensated chronic cirrhosis in combination with ribavirin.
Velakast treatment is determined by the hepatitis C virus genotype:
Genotype I and II for 3 months.
With genotype III, treatment lasts 3 months, if ribavirin is included in the therapy, otherwise – 6 months. These rules are valid only for those patients who have already undergone therapy before. With the initial treatment, Velakast is always taken for 12 weeks.
In the case of hepatitis C genotypes IV, V and VI, the drug is prescribed for 12 weeks.
Do not use Velakast after the expiration date in order to avoid intoxication of the body.
In case of an overdose of Velakast, poisoning can be observed, so an urgent visit to the attending physician is required.
The use of VELAKAST and ribavirin should not be prescribed to those patients for whom ribavirin is contraindicated.
Studies on the effects of Velakast have been conducted only in patients over 12 years of age. But in view of a small sample, you should not use the drug for people under 18 years of age.
There is also insufficient data on the effect of Velakast on the baby and the fetus, so you should not consume the medicine for pregnant women, mothers during lactation and couples planning to have a baby.
Attention should be paid to the use of Velakast and the effects of it on those patients whose age has exceeded 65 years, as well as patients on hemodialysis or with bradycardia.
Interaction with other medicines
Some drugs taken in parallel with Velakast can cause unpleasant symptoms, slower absorption, or weaken the effect of sofosbuvir and velpatasvir. The list of such funds includes:
- cardiac glycosides;
- St. John’s wort
- antacid preparations;
- anticonvulsant drugs.
Method of administration and dosage
The recommended dosage of VELAKAST is 1 tablet taken orally once a day with or without food.
- Velakast should be washed down with a sufficient amount of boiled water.
- Do not gnaw or break the tablet due to the bitter taste.
- One dragee per day is sufficient, and it is better to appoint Velakast at the same time per day.
- If one tablet has been missed, take the pills in the next 12 hours.
- The effectiveness of the treatment does not depend on the combination of tablets with food, so Velakast can be drunk with food, as well as before or after.
Most patients tolerate sofosbuvir and its combinations with other components, including velpatasvir, well. In 5-10% of cases, such forms of discomfort as:
- allergic reactions;
- reduced ability to work;
- bouts of nausea;
- constipation and diarrhea.
As a rule, many of these symptoms are associated primarily with the additional use of ribavirin. In general, side effects go away on their own.